PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is making progress in the development of its second pipeline drug, CF102, for the treatment of liver diseases and in particular liver cancer. The first dose cohort of a phase I clinical trial was successfully completed. Initiation of this phase I trial was enabled by a recently approved FDA IND application submitted by the Company. This trial is currently being conducted in the US by a clinical research organization (CRO), specializing in the conductance of Phase I studies. The drug is orally administered to healthy volunteers in sequential dose-escalating cohorts. Now that the first trial cohort with the lower drug dose has been successfully completed, Can-Fite can proceed to the next trial cohort with a higher dose.
